{"id":"W2794845062","doi":"10.1016/j.jaad.2018.03.037","title":"Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial","year":2018,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":188,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Placebo; Psoriasis; Clinical endpoint; Psoriasis Area and Severity Index; Adverse effect; Internal medicine; Interleukin 17; Randomized controlled trial; Gastroenterology; Clinical trial; Interleukin; Surgery; Immunology; Inflammation; Cytokine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00208214,0.001826867,0.003818905,0.0005563762,0.0005898848,0.001751758,0.0009413007,0.002460891,0.005473655],"category_scores_gemma":[0.001435547,0.0008040533,0.002636639,0.0004101921,0.001191245,0.001633139,0.0004111207,0.004351089,0.0012199],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005925676,"about_ca_system_score_gemma":0.0007537431,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007131946,"about_ca_topic_score_gemma":0.001323883,"domain_scores_codex":[0.9993379,0.000274243,0.00004823622,0.0001314113,0.00006846321,0.0001396991],"domain_scores_gemma":[0.9993211,0.0001902508,0.0001369327,0.00005946312,0.00004885648,0.0002435325],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9506955,0.00858717,0.0007535368,0.001219498,0.001746904,0.00007380279,0.0000924112,0.0002816975,0.005992162,0.0001207468,0.001297749,0.02913882],"study_design_scores_gemma":[0.965183,0.03174478,0.001313974,0.00003892987,0.0005115891,0.00004560005,0.00002527231,0.0001335809,0.0003533881,0.0001061658,0.000531402,0.00001245411],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9726241,0.01806417,0.0008942693,0.001438598,0.0008286777,0.002047386,0.001309762,0.0001812084,0.002611791],"genre_scores_gemma":[0.9798421,0.008054097,0.001534126,0.002169794,0.0007310488,0.001946706,0.001420888,0.00005003469,0.004251209],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005473655,"threshold_uncertainty_score":0.01831114,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02089051072143032,"score_gpt":0.2762123065281997,"score_spread":0.2553217958067694,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}